This clinical trial is focused on studying Chronic Rhinosinusitis with Nasal Polyps, a condition where the nasal passages become inflamed and develop growths called polyps. The study will evaluate the effectiveness and safety of a treatment called Lebrikizumab, which is given as a solution for injection. Participants will receive either Lebrikizumab or a placebo, while continuing their usual treatment with intranasal corticosteroids, which are medications sprayed into the nose to reduce inflammation.
The purpose of the study is to see how well Lebrikizumab works in reducing nasal congestion and the size of nasal polyps over a period of 24 weeks. Participants will be randomly assigned to receive either the treatment or the placebo, and neither the participants nor the researchers will know who is receiving which, to ensure unbiased results. The study will involve regular check-ups and assessments to monitor the condition of the participants and the effects of the treatment.
Throughout the study, participants will be asked to report their nasal congestion symptoms using a simple scale, and the size of their nasal polyps will be evaluated through a procedure called nasal endoscopy, which involves using a small camera to look inside the nose. The study aims to provide valuable information on whether Lebrikizumab can be an effective treatment option for people with Chronic Rhinosinusitis with Nasal Polyps.
Belgium 
Bulgaria 
Denmark 
Finland 
Germany 
Hungary 
Italy 
Poland 
Portugal 
Romania 
Spain 